Approval · Notice of Compliance 25419 · 2021
KEYTRUDA: Notice of Compliance 25419
Issued March 3, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25419
- Date
- March 3, 2021
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: keytruda is indicated as monotherapy for the first-line treatment of adult patients with metastatic msi-h or dmmr colorectal cancer
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| KEYTRUDA | Not yet assigned | — |
Medicinal ingredients
- PEMBROLIZUMAB 25 MG per ML
- PEMBROLIZUMAB 50 MG per VIAL